Clinical trials: Gemcitabine
Advanced Cancer, Metastatic Melanoma
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
The purpose of this study is to determine the safety of an extracellular signal regulated kinase (ERK1/2) inhibitor LY3214996 administered alone or in combination with other agents in participants with advanced cancer.
- Conditions
- Advanced Cancer, Metastatic Melanoma, Metastatic Non-small Cell Lung Cancer, Colorectal Cancer
- Trial name
- NCT02857270
- Testing
- LY3214996, Midazolam, Abemaciclib
- Where
- 13 sites in United States, Australia and 2 more
- Volunteers
- 210 people
- Sponsor
- Eli Lilly and Company
Metastatic Urothelial Cancer
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
The objective of this study is to evaluate the efficacy and safety of sacituzumab govitecan-hziy monotherapy and with novel combinations in participants with metastatic urothelial cancer (mUC).
- Trial name
- TROPHY U-01 (NCT03547973)
- Testing
- Sacituzumab Govitecan-hziy, Pembrolizumab, Cisplatin
- Where
- 128 sites in United States, France and 7 more
- Volunteers
- 502 people
- Sponsor
- Gilead Sciences
Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma
AB122 Platform Study
This is a phase 1, non-randomized open-label, multicenter platform study designed to evaluate the tolerability and safety of AB122 in patients with malignancies specified in each cohort.
- Conditions
- Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT04999761
- Testing
- AB122, TAS-116, TAS-120
- Where
- 9 sites in Japan
- Volunteers
- 917 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer
A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]
This randomized, open-label study will evaluate the efficacy and safety of atezolizumab compared with chemotherapy consisting of a platinum agent (cisplatin or carboplatin per investigator discretion) combined with either…
- Trial name
- NCT02409342
- Testing
- Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody, Carboplatin, Cisplatin
- Where
- 142 sites in United States, Brazil and 17 more
- Volunteers
- 572 people
- Sponsor
- Hoffmann-La Roche
Solid Tumors
Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM060184 in Combination With Gemcitabine in Selected Patients With Advanced Solid Tumors
Prospective, open-label, dose-ranging, uncontrolled phase I study with escalating doses of PM060184 in combination with gemcitabine in selected patients with advanced solid tumors.
- Trial name
- NCT02533674
- Testing
- Gemcitabine plus PM060184
- Where
- 2 sites in United States, Spain
- Volunteers
- 57 people
- Sponsor
- PharmaMar
Pancreatobiliary Cancers, Pancreatic Ductal Adenocarcinoma
A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary Cancers
Cancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably. The pancreas is a gland behind the stomach that produces a digestive fluid that is emptied into the intestines through tube…
- Trial name
- NCT07769502
- Testing
- Telisotuzumab Adizutecan, Gemcitabine, Nab-Paclitaxel
- Where
- 7 sites in United States, Israel and 2 more
- Volunteers
- 168 people
- Sponsor
- AbbVie
Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
This Phase II trial evaluates the optimization of the cytokine release syndrome (CRS) profile for glofitamab in combination with gemcitabine and oxaliplatin (Glofit-GemOx) followed by glofitamab monotherapy treatment regimen (Cohort…
- Trial name
- NCT06806033
- Testing
- Obinutuzumab, Glofitamab, Gemcitabine
- Where
- 53 sites in United States, Australia and 5 more
- Volunteers
- 130 people
- Sponsor
- Hoffmann-La Roche
Metastatic Pancreatic Cancer
Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas
Phase III Metastatic Pancreatic Cancer
- Trial name
- NCT00844649
- Testing
- Albumin-bound paclitaxel (ABI-007), Gemcitabine
- Where
- 193 sites in United States, Australia and 9 more
- Volunteers
- 861 people
- Sponsor
- Celgene
Non-Small-Cell Lung Carcinoma
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
This is a Phase IIb/III randomized, double-blind, placebo-controlled study to compare the efficacy and safety of first-line therapy combined with TG4010 or placebo in stage IV non-small cell lung cancer (NSCLC).
- Trial name
- TIME (NCT01383148)
- Testing
- TG4010
- Where
- 72 sites in United States, Belgium and 8 more
- Volunteers
- 222 people
- Sponsor
- Transgene
Solid Tumor
A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors
This study aims to evaluate the efficacy and safety of QLS31905 plus chemotherapy in patients with Claudin18.2-positive advanced solid tumors.
- Trial name
- NCT06041035
- Testing
- QLS31905, Nab paclitaxel, Gemcitabine
- Where
- China
- Volunteers
- 115 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Triple Negative Breast Neoplasms
Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)
The purpose of this study is to compare the efficacy of olaparib (MK-7339) plus pembrolizumab (MK-3475) with chemotherapy plus pembrolizumab after induction with first-line chemotherapy plus pembrolizumab in triple negative…
- Trial name
- NCT04191135
- Testing
- Pembrolizumab, Olaparib, Carboplatin
- Where
- 122 sites in United States, Canada and 13 more
- Volunteers
- 462 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Cancer, Cancer
BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors
This is a Phase 1a/b multicenter, open-label, non-randomized, dose-escalation study to examine the dose limiting toxicities (DLT) of BPM31510 administered as a 144-hour continuous intravenous (IV) infusion as…
- Conditions
- Metastatic Cancer, Cancer, Solid Tumor
- Trial name
- NCT01957735
- Testing
- BP31510 monotherapy, BP31510 in combination with chemotherapy
- Where
- 3 sites in United States
- Volunteers
- 97 people
- Sponsor
- BPGbio
Carcinoma, Pancreas
A Phase 1-2, XIAP Antisense AEG35156 With Gemcitabine in Patients With Advanced Pancreatic Cancer
This is an open-label multicenter, phase 1-2 study. Following determination of the recommended AEG35156 dose in combination with gemcitabine in the initial Phase 1 part of this study, additional patients will be enrolled in the…
- Trial name
- NCT00557596
- Testing
- AEG35156
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Aegera Therapeutics
Bladder Cancer
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
The purpose of this study is to assess the antitumor efficacy and safety of perioperative enfortumab vedotin (EV) plus pembrolizumab and radical cystectomy (RC) + pelvic lymph node dissection (PLND) compared with the current…
- Trial name
- KEYNOTE-B15 (NCT04700124)
- Testing
- Pembrolizumab, Enfortumab vedotin (EV), RC + PLND
- Where
- 188 sites in United States, Argentina and 27 more
- Volunteers
- 808 people
- Sponsor
- Merck Sharp & Dohme LLC
Locally Advanced or Metastatic NSCL Cancer Stage IIIB IV
Assess Safety & Efficacy of Selumetinib When Given in Combination With Standard First Line Treatment for Advanced Non-small Cell Lung Cancer
This is a Phase I, open label multicentre study of selumetinib administered orally in combination with first line chemotherapy regimens to patients with advanced/metastatic NSCLC.
- Trial name
- SELECT-3 (NCT01809210)
- Testing
- selumetinib, gemcitabine, cisplatin
- Where
- 4 sites in United Kingdom
- Volunteers
- 55 people
- Sponsor
- AstraZeneca
Solid Tumors
A Phase I Clinical Study of Oral CP-4126 in Patients With Advanced Solid Tumour
At step 1, patients with advanced solid tumors will receive CP-4126 capsules following a dose escalation schedule until the maximum tolerated dose is reached. At step 2, 20 patients will be randomized.
- Trial name
- NCT00778128
- Testing
- CP-4126, Gemcitabine
- Where
- 3 sites in Belgium, Netherlands
- Volunteers
- 26 people
- Sponsor
- Clavis Pharma
Diffuse Large B Cell Lymphoma
Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
To explore the efficacy and safety of TQB2825 injection combined immunochemotherapy in subjects with untreated or R/R DLBCL. The efficacy evaluation indicators are objective response rate (ORR), complete response rate (CR…
- Trial name
- NCT06829771
- Testing
- TQB2825 injection +R-CHOP regimen, TQB2825 injection + GemOx
- Where
- 25 sites in China
- Volunteers
- 90 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Triple Negative Breast Cancer, PD-L1 Negative
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of physician's choice (TPC) in participants with previously untreated, locally…
- Trial name
- ASCENT-03 (NCT05382299)
- Testing
- Sacituzumab Govitecan-hziy, Paclitaxel, nab-Paclitaxel
- Where
- 363 sites in United States, Argentina and 28 more
- Volunteers
- 623 people
- Sponsor
- Gilead Sciences
Solid Tumor
A Study of LY3200882 in Participants With Solid Tumors
The main purpose of this study is to evaluate the safety of the study drug known as LY3200882 in participants with solid tumors.
- Trial name
- NCT02937272
- Testing
- LY3200882, LY3300054, Gemcitabine
- Where
- 18 sites in United States, Australia and 6 more
- Volunteers
- 223 people
- Sponsor
- Eli Lilly and Company
Metastatic Pancreatic Cancer
Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer
To evaluate the safety and efficacy of ACP-196 and nab paclitaxel/gemcitabine in subjects with previously untreated metastatic pancreatic cancer using standard response criteria
- Trial name
- NCT02570711
- Testing
- ACP-196, Nab-paclitaxel, Gemcitabine
- Where
- 10 sites in United States
- Volunteers
- 3 people
- Sponsor
- Acerta Pharma BV